Prospective Evaluation of the Impact of the 21‐Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node‐Positive Breast Cancer in Ontario, Canada

BACKGROUND. The 21‐gene Recurrence Score (RS) assay is only reimbursed in Ontario for node‐negative and micrometastatic node‐positive (N+) early‐stage breast cancer (EBC). We carried out a prospective study to evaluate the impact of the assay on treatment decisions for women with N+ EBC. SUBJECTS, M...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Torres, Sofia, Trudeau, Maureen, Gandhi, Sonal, Warner, Ellen, Verma, Sunil, Pritchard, Kathleen I., Petrella, Teresa, Hew‐Shue, Mark, Chao, Calvin, Eisen, Andrea
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2018
Assuntos:
Breast Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6058344/
https://ncbi.nlm.nih.gov/pubmed/29371476
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0346
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados